Evidence map›Paper›PMID 39539266›Full record

ReviewACS pharmacology & translational science2024

Understanding Comorbidities of Respiratory Models as Novel Platforms for Drug Discovery.

Simone N De Luca, Avanka Gunatilaka, Madison Coward-Smith, Henry M Gomez, Richard Y Kim, Aimee Stenekes, Stanley M H Chan, Wei Wang, Daniel Tan, Ross Vlahos and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ACS pharmacology & translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Simone N De LucaRespiratory Research Group, Centre for Respiratory Science and Health, School of Health and Biomedical Sciences, RMIT University, Bundoora, Melbourne, Victoria 3083, Australia.
Avanka GunatilakaDepartment of Biochemistry and Pharmacology, The University of Melbourne, Parkville, Victoria 3010, Australia.
Madison Coward-SmithRespiratory Research Group, Centre for Respiratory Science and Health, School of Health and Biomedical Sciences, RMIT University, Bundoora, Melbourne, Victoria 3083, Australia.
Henry M GomezSchool of Biomedical Sciences and Pharmacy, University of Newcastle and Immune Health Program, Hunter Medical Research Institute, Newcastle, New South Wales 2308, Australia.
Richard Y KimSchool of Life Sciences, University of Technology Sydney, Sydney, New South Wales 2007, Australia.
Aimee StenekesSchool of Life Sciences, University of Technology Sydney, Sydney, New South Wales 2007, Australia.
Stanley M H ChanRespiratory Research Group, Centre for Respiratory Science and Health, School of Health and Biomedical Sciences, RMIT University, Bundoora, Melbourne, Victoria 3083, Australia.
Wei WangRespiratory Research Group, Centre for Respiratory Science and Health, School of Health and Biomedical Sciences, RMIT University, Bundoora, Melbourne, Victoria 3083, Australia.
Daniel TanDepartment of Biochemistry and Pharmacology, The University of Melbourne, Parkville, Victoria 3010, Australia.
Ross VlahosRespiratory Research Group, Centre for Respiratory Science and Health, School of Health and Biomedical Sciences, RMIT University, Bundoora, Melbourne, Victoria 3083, Australia.
Alastair G StewartDepartment of Biochemistry and Pharmacology, The University of Melbourne, Parkville, Victoria 3010, Australia.ORCID https://orcid.org/0000-0002-2271-5942
Chantal DonovanSchool of Life Sciences, University of Technology Sydney, Sydney, New South Wales 2007, Australia.ORCID https://orcid.org/0000-0003-4558-329X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic respiratory diseases affect over 450 million people worldwide and result in 4 million deaths per year. The majority of lung diseases are treated with drugs delivered directly to the lungs. However, there is bidirectional crosstalk between the lung and other organs/tissues in health and disease. This crosstalk supports targeting of extrapulmonary sites in addition to the lung to improve the comorbidities associated with lung disease. However, new preclinical

Identifiers

PMID39539266
PMCPMC11555503

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.